


Valganciclovir

Indications: Treatment and prevention of herpesvirus family infections, primarily **cytomegalovirus (CMV)** infection

Mechanism of action: **Prodrug of ganciclovir**. Rapidly absorbed and **converted to Ganciclovir** by first-pass metabolism, by intestinal and hepatic esterases

Oral **bioavailability** is approximately **60%**, compared to IV Ganciclovir



Use in Pregnancy/ Breast feeding:
Teratogenicity in animal studies
Avoid unless benefit outweighs risk

Use in Renal impairment:
Dose adjustment required
Increased risk of toxicity

Dose: Oral only. (Use Ganciclovir if IV required)

Used for: prevention of CMV disease (eg mismatched SOT recipients)

And: induction and/or maintenance tx of CMV disease if can absorb orals

Adverse effects (please see BNF)

Bone marrow suppression – significant risk

Renal toxicity

Neurotoxicity